BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35180142)

  • 1. Vitamin B12 enhances the antitumor activity of 1,25-dihydroxyvitamin D3 via activation of caspases and targeting actin cytoskeleton.
    Atoum MF; Alzoughool FE; Al-Mazaydeh ZA; Rammaha MS; Tahtamouni LH
    Tumour Biol; 2022; 44(1):17-35. PubMed ID: 35180142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1α,25-Dihydroxyvitamin D
    Ben-Eltriki M; Deb S; Guns EST
    J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.
    Ravid A; Rocker D; Machlenkin A; Rotem C; Hochman A; Kessler-Icekson G; Liberman UA; Koren R
    Cancer Res; 1999 Feb; 59(4):862-7. PubMed ID: 10029076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,25-Dihydroxyvitamin D
    Li M; Li L; Zhang L; Hu W; Shen J; Xiao Z; Wu X; Chan FL; Cho CH
    Life Sci; 2017 Jun; 179():88-97. PubMed ID: 28465245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,25-Dihydroxyvitamin D₃ and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells.
    Bao A; Li Y; Tong Y; Zheng H; Wu W; Wei C
    Int J Mol Med; 2014 May; 33(5):1177-84. PubMed ID: 24573222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.
    Reichrath J; Rech M; Moeini M; Meese E; Tilgen W; Seifert M
    Cancer Biol Ther; 2007 Jan; 6(1):48-55. PubMed ID: 17172823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
    Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
    J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Synergistic inhibitory effect of all-trans retinoic acid and 1,25-dihydroxy vitamin D3 on growth of human hepatoma cell line HepG2].
    Lu HQ; Zheng J
    Ai Zheng; 2006 Dec; 25(12):1470-6. PubMed ID: 17166369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH; Zhao XY; Holloway L; Feldman D
    Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,25-Dihydroxy vitamin D3 inhibits the Ras-MEK-ERK pathway and regulates proliferation and apoptosis of papillary thyroid carcinoma.
    Li B; Lv L; Li W
    Steroids; 2020 Jul; 159():108585. PubMed ID: 31982425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fish oil enhances the antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 on liver cancer cells.
    Chiang KC; Persons KS; Istfan NW; Holick MF; Chen TC
    Anticancer Res; 2009 Sep; 29(9):3591-6. PubMed ID: 19667153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel analogs of 1,25-dihydroxyvitamin D
    Nachliely M; Sharony E; Kutner A; Danilenko M
    J Steroid Biochem Mol Biol; 2016 Nov; 164():59-65. PubMed ID: 26365556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating and antitumor activities of 1 alpha,25-dihydroxyvitamin D3 in vitro and 1 alpha-hydroxyvitamin D3 in vivo on human osteosarcoma.
    Tsuchiya H; Morishita H; Tomita K; Ueda Y; Tanaka M
    J Orthop Res; 1993 Jan; 11(1):122-30. PubMed ID: 8423514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
    Gavrilov V; Steiner M; Shany S
    Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)
    Narvaez CJ; Bak MJ; Salman N; Welsh J
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106307. PubMed ID: 37030416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells.
    Simboli-Campbell M; Narvaez CJ; van Weelden K; Tenniswood M; Welsh J
    Breast Cancer Res Treat; 1997 Jan; 42(1):31-41. PubMed ID: 9116316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog.
    Berkovich L; Ben-Shabat S; Sintov AC
    Anticancer Drugs; 2010 Jul; 21(6):609-18. PubMed ID: 20335794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
    Moffatt KA; Johannes WU; Miller GJ
    Clin Cancer Res; 1999 Mar; 5(3):695-703. PubMed ID: 10100724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a vitamin D3-resistant MCF-7 cell line.
    Narvaez CJ; Vanweelden K; Byrne I; Welsh J
    Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.